BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Stem Cells. Mar 26, 2026; 18(3): 116298
Published online Mar 26, 2026. doi: 10.4252/wjsc.v18.i3.116298
Prospective evaluation of autologous bone marrow-derived mesenchymal stem cell injection in meniscal injury
Xiang Fu, Hui Song, Jiu-Song Wu, Xu Chen
Xiang Fu, Department of Orthopedics, The Third People’s Hospital of Haikou City, Haikou 571100, Hainan Province, China
Hui Song, Department of Outpatient, Shanxi Tumor Hospital Taiyuan, Taiyuan 030013, Shanxi Province, China
Jiu-Song Wu, Department of Orthopedics, Yongchuan District People’s Hospital of Chongqing, Chongqing 402160, China
Xu Chen, Department of Arthroplasty, The Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi 830002, Xinjiang Uygur Autonomous Region, China
Co-first authors: Xiang Fu and Hui Song.
Author contributions: Fu X and Song H contributed equally to this work and are co-first authors. Fu X designed the study, performed the data analysis, and drafted the initial manuscript; Song H participated in patient recruitment, data collection, and statistical analysis; Wu JS contributed to study design, interpretation of data, and critical revision of the manuscript for important intellectual content; Chen X supervised the entire study, provided methodological guidance, and served as the corresponding author. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.
Supported by Guangdong Basic and Applied Basic Research Foundation, No. 2021A1515110882.
Institutional review board statement: This study has been reviewed and approved by the Medical Ethics Committee of the Third People’s Hospital of Haikou City, approval No. 2023-(lunshen)-356.
Clinical trial registration statement: This study was not registered in a public clinical trial registry, as it was a prospective single-arm exploratory study; however, it was approved by the institutional ethics committee and conducted in accordance with ethical standards.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No data available.
Corresponding author: Xu Chen, MD, Associate Chief Physician, Department of Arthroplasty, The Sixth Affiliated Hospital of Xinjiang Medical University, No. 39 Wuxing South Road, Tianshan District, Urumqi 830002, Xinjiang Uygur Autonomous Region, China. chenxu0041@126.com
Received: December 9, 2025
Revised: January 12, 2026
Accepted: February 12, 2026
Published online: March 26, 2026
Processing time: 106 Days and 0.3 Hours
Core Tip

Core Tip: This prospective clinical study examined the therapeutic efficacy of autologous bone marrow-derived mesenchymal stem cell injections in patients with chronic meniscal injuries. Significant pain reduction and functional improvement were observed over 12 months. This was supported by enhanced Visual Analog Scale pain, International Knee Documentation Committee, and Lysholm scores, as well as magnetic resonance imaging T2 mapping, indicating enhanced meniscal tissue quality. The intervention proved to be safe, minimally invasive, and well-tolerated, suggesting that bone marrow-derived mesenchymal stem cell therapy could offer a viable regenerative option to surgery for chronic meniscal injuries. This approach may facilitate both structural restoration and clinical recovery.